Lezárult
Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer
NCT07285564· Centre Henri Becquerel· Forrás
Lezárult
FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
NCT06592846· The Lymphoma Academic Research Organisation· Forrás
Lezárult
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
2023-505910-10-00· 2. fázis· Ryvu Therapeutics S.A.· Forrás
Fut, nem toboroz
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-503428-24-00· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Pfizer· Forrás
Lezárult
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
NCT06141772· Centre Henri Becquerel· Forrás
Toboroz
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT05581121· 3. fázis· Institut Claudius Regaud· Forrás
Lezárult
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.
2022-502584-38-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Lezárult
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)
2023-508528-36-00· 3. fázis· Merck Healthcare KGaA· Forrás
Lezárult
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
NCT05355987· Centre Henri Becquerel· Forrás
Lezárult
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
NCT05303129· Centre Francois Baclesse· Forrás
Fut, nem toboroz
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
NCT04980222· 2. fázis· Hoffmann-La Roche· Forrás
Lezárult
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT05008224· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Leállították
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT04809467· 1/2. fázis· Incyte Corporation· Forrás
Lezárult
ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS
NCT04857645· 2. fázis· Groupe Francophone Des Myelodysplasies· Forrás
Lezárult
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
2023-507497-40-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
NCT04827719· 2. fázis· Groupe Francophone des Myelodysplasies· Forrás
Lezárult
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
NCT04703686· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Fut, nem toboroz
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· 3. fázis· ADC Therapeutics S.A.· Forrás
Fut, nem toboroz
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Lezárult
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· 3. fázis· AstraZeneca· Forrás
Lezárult
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04182204· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
NCT04199104· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer
2022-500418-24-00· 2/3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer
NCT04008095· University Hospital, Brest· Forrás
Lezárult
Molecular Profiling of Advanced Soft-tissue Sarcomas
NCT03784014· 3. fázis· Institut National de la Santé Et de la Recherche Médicale, France· Forrás
Lezárult
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
NCT03993912· 3. fázis· University Hospital, Lille· Forrás
Lezárult
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
NCT03838263· 2. fázis· UNICANCER· Forrás
Lezárult
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer
NCT03879109· 3. fázis· University Hospital, Bordeaux· Forrás
Lezárult
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment
NCT03832348· Centre Henri Becquerel· Forrás
Lezárult
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
NCT03723967· 2. fázis· Centre Leon Berard· Forrás
Lezárult
Phase II Study of Regorafenib as Maintenance Therapy
NCT03793361· 2. fázis· Centre Oscar Lambret· Forrás
Lezárult
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
NCT03818061· 2. fázis· Centre Leon Berard· Forrás
Lezárult
Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1
2024-515352-20-00· 2. fázis· Groupe Francophone Des Myelodysplasies· Forrás
Lezárult
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
NCT04069468· Boston Scientific Corporation· Forrás
Lezárult
UTOLA: UTerin OLAparib
NCT03745950· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Lezárult
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
NCT03339843· 2. fázis· Jules Bordet Institute· Forrás
Lezárult
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
2024-515533-15-00· 2. fázis· Institut Gustave Roussy· Forrás
Lezárult
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585· 3. fázis· Daiichi Sankyo· Forrás
Lezárult
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
NCT03594149· 3. fázis· Centre Henri Becquerel· Forrás
Lezárult
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
NCT03467373· 1. fázis· Hoffmann-La Roche· Forrás
Lezárult
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
NCT03275506· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Lezárult
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
NCT03235544· 2. fázis· Incyte Corporation· Forrás
Lezárult
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017· 2. fázis· BeiGene· Forrás
Lezárult
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
NCT02896582· 2. fázis· The Lymphoma Academic Research Organisation· Forrás
Lezárult
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
NCT02924402· 1. fázis· Xencor, Inc.· Forrás
Lezárult
ROLLOVER STUDY FOR TAZEMETOSTAT
NCT02875548· 1/2. fázis· Epizyme Inc.· Forrás
Lezárult
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
NCT02815137· Centre Henri Becquerel· Forrás
Showing 50 of 59.